E-mail

E-mail a Wiley Online Library Link

Matthew D. Galsky, Susan Krege, Chia-Chi Lin, Noah Hahn, Thorsten Ecke, Erin Moshier, Guru Sonpavde, James Godbold, William K. Oh and Aristotle Bamias Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy Cancer 119

Article first published online: 29 MAY 2013 | DOI: 10.1002/cncr.28145

Response rate has traditionally been used as the primary endpoint of phase 2 trials in metastatic urothelial cancer but may be problematic in screening the activity of novel combination regimens. The current analysis demonstrates that progression-free survival, measured at fixed time points, is highly correlated with overall survival in patients with metastatic urothelial cancer treated with cisplatin-based chemotherapy and may be a more attractive intermediate endpoint in this clinical disease state.

Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf

Required = Required Field

Choose captcha format: Image or Audio. Click here if you need help.

SEARCH